

SHORT SYNTHESIS OF 6-OXOPROSTAGLANDIN E<sub>1</sub> AND 6-OXOPROSTAGLANDIN F<sub>1α</sub><sup>1</sup>

T. Tanaka, A. Hazato, K. Bannai, N. Okamura, S. Sugiura, K. Manabe, and S. Kurozumi<sup>\*</sup>  
Institute for Bio-Medical Research, Teijin Ltd., 4-3-2 Asahigaoka, Hino, Tokyo 191, Japan  
M. Suzuki and R. Noyori<sup>\*</sup>










Department of Chemistry, Nagoya University, Chikusa, Nagoya 464, Japan

**Summary:** 6-Oxoprostaglandin E<sub>1</sub> methyl ester was synthesized in a single pot from (R)-4-*t*-butyldimethylsiloxy-2-cyclopentenone by organocopper conjugate addition with an ω side-chain unit, trapping of the resulting enolate with 6-methoxycarbonyl-2-nitrohex-1-ene, and treatment with aqueous titanium(III) trichloride. Hydrolysis of the methyl ester was accomplished by porcine liver esterase. 6-Oxoprostaglandin F<sub>1α</sub> was obtained from 6-nitroprostoglandin E<sub>1</sub> methyl ester in four steps.

6-Oxoprostaglandin E<sub>1</sub> (6-oxo-PGE<sub>1</sub>, 7), an active metabolite<sup>2</sup> of PGI<sub>2</sub>, is known to be one of the most powerful vaso-active metabolites<sup>3,4</sup> in arachidonic acid cascade. On the other hand, 6-oxo-PGF<sub>1α</sub> (12) is an inactive metabolite derived from PGI<sub>2</sub> by hydration and, consequently, is a useful compound as a diagnostic parameter<sup>5</sup> representing the concentration of PGI<sub>2</sub> under physiological conditions. 6-Oxo-PGE<sub>1</sub> (7) has so far been synthesized only from PGI<sub>2</sub> via oxidation<sup>6</sup> of a 6-oxo-PGF<sub>1α</sub> derivative.<sup>7</sup> Reported herein is the direct, *de novo* synthesis of these two 6-oxo-PGs.

In the course of exploring the short way to PGE<sub>1</sub><sup>8</sup> via the three-component coupling process,<sup>9</sup> we have been prompted to find a facile entry to 6-oxo-PGE<sub>1</sub> (7). On the basis of dissection of the 1,4-diketone structure 7, coupled with the characteristic of our synthetic strategy,<sup>8,9</sup> conversion of the nitronate intermediate 4 should be one of the most promising ways leading to the oxo derivative. The generation of the anion 4 could be achieved by the combination of the optically active cyclopentenone block 1<sup>9a,10</sup> and the ω side-chain unit 2 via the organocopper conjugate addition, followed by Michael trapping of the resulting enolate by the nitro-olefin 3.<sup>8</sup> The Nef reaction conditions<sup>11</sup> would be among the most appropriate for the conversion of the anionic intermediate to the oxo compound, thereby realizing a single-pot construction of the PG skeleton which possesses the desired oxidation states.

The vinyl copper reagent 12a,b was prepared by treatment of the vinylic iodide 2,<sup>13</sup> [ $\alpha$ ]<sub>D</sub><sup>21</sup> -30.6° (c 1.57, CCl<sub>4</sub>), with 2 equiv of *t*-butyllithium in ether at -78 °C for 2 h followed by addition of an ethereal solution of copper(I) iodide<sup>12c</sup> (1 equiv) and tributylphosphine (2 equiv). Reaction of the vinylcopper reagent with 0.77 equiv of the enone 1, [ $\alpha$ ]<sub>D</sub><sup>22</sup> +63.2° (c 1.04, CH<sub>3</sub>OH, 94.3% ee<sup>14</sup>), at -78 °C for 15 min and then at -40 °C for 30 min, followed by treatment with 0.77 equiv of the nitro-olefin 3 at -40 °C for 30 min. Exposure of the mixture to aqueous THF solution of titanium(III) trichloride (12 equiv) and ammonium acetate (72 equiv) at room temperature for 18 h gave the 6-oxo-PGE<sub>1</sub> derivative 5<sup>15</sup> in 66% isolated yield, [ $\alpha$ ]<sub>D</sub><sup>22</sup> -39.3° (c

**1****2****3****4**, R = Si(CH<sub>3</sub>)<sub>2</sub>-*t*-C<sub>4</sub>H<sub>9</sub>**5**, R = Si(CH<sub>3</sub>)<sub>2</sub>-*t*-C<sub>4</sub>H<sub>9</sub>; R' = CH<sub>3</sub>**6**, R = H; R' = CH<sub>3</sub>**7**, R = R' = H**8**, R = Si(CH<sub>3</sub>)<sub>2</sub>-*t*-C<sub>4</sub>H<sub>9</sub>**9a**, 9 $\alpha$ -OH; R = Si(CH<sub>3</sub>)<sub>2</sub>-*t*-C<sub>4</sub>H<sub>9</sub>**9b**, 9 $\beta$ -OH; R = Si(CH<sub>3</sub>)<sub>2</sub>-*t*-C<sub>4</sub>H<sub>9</sub>**10a**, 9 $\alpha$ -OH; R = Si(CH<sub>3</sub>)<sub>2</sub>-*t*-C<sub>4</sub>H<sub>9</sub>;  
R' = CH<sub>3</sub>**10b**, 9 $\beta$ -OH; R = Si(CH<sub>3</sub>)<sub>2</sub>-*t*-C<sub>4</sub>H<sub>9</sub>;  
R' = CH<sub>3</sub>**11**, R' = CH<sub>3</sub>**12**, R' = H

1.04, CH<sub>3</sub>OH). In addition, the C-8 epimer,  $[\alpha]_D^{22} +28^\circ$  ( $c$  0.55, CH<sub>3</sub>OH), was obtained in 10% yield.<sup>16</sup> This was epimerized easily to 5 on a silica gel TLC plate. Desilylation of 5 with hydrogen fluoride-pyridine in acetonitrile (room temp, 3 h) produced 6-oxo-PGE<sub>1</sub> methyl ester (6)<sup>15</sup> (92%),  $[\alpha]_D^{21} -48.5^\circ$  ( $c$  0.71, CH<sub>3</sub>OH), mp 44.0–44.5 °C (recrystallized from hexane-ether, lit.<sup>7a</sup> mp 39–40 °C). Hydrolysis of 6 with porcine liver esterase<sup>17</sup> (room temp, 18 h) completed the synthesis of naturally occurring 6-oxo-PGE<sub>1</sub> (7)<sup>15</sup> (89% yield),  $[\alpha]_D^{20} -50.0^\circ$  ( $c$  1.55, CH<sub>3</sub>OH), mp 65 °C (recrystallized from hexane-ether, lit.<sup>7a</sup> mp 67–69 °C). Thus conversion of the *in situ* generated nitronate intermediate 4 into the oxo compound 5 worked quite smoothly. However, attempted nitro to oxo conversion using the neutral 6-nitro compound 8 (a mixture of C-6 epimers)<sup>8</sup> under the original or modified Nef reaction conditions<sup>11</sup> did not meet with great success because of the instability of the oxygenated cyclopentanone moiety. The desired 6-oxo compound 5 was obtained only by treatment with the combination of triphenylphosphine and buffered titanium(III) trichloride<sup>11b</sup> at room temperature for 5 h (16% yield).

6-Oxo-PGF<sub>1α</sub> (12) was synthesized from the protected 6-nitro-PGE<sub>1</sub> (8)<sup>8</sup> by the following four-step procedure. Reduction of 8 with diisobutylaluminum 2,6-di-*t*-butyl-4-methylphenoxide<sup>18</sup> (5 equiv) in toluene at -78 °C for 3.5 h gave a mixture of the 9α alcohol, 9a, and its 9β isomer, 9b, in 80% yield (9a:9b = 7:1). The nitronate intermediate formed by exposure of the mixture to 1 equiv of sodium methoxide in methanol at 0 °C for 3 min was treated with a mixture of 10 equiv of titanium(III) trichloride and 60 equiv of ammonium acetate in aqueous THF<sup>11b</sup> at room temperature for 18 h to give, after silica gel chromatography, the corresponding 6-oxo alcohols, 10a (63%),  $[\alpha]_D^{20} -10^\circ$  ( $c$  2.48, CH<sub>3</sub>OH), and 10b (9%),  $[\alpha]_D^{20} -3.5^\circ$  ( $c$  0.96, CH<sub>3</sub>OH). Removal of the silyl groups from 10a with hydrogen fluoride-pyridine (room temp, 1 h) provided 6-oxo-PGF<sub>1α</sub> methyl ester (11)<sup>15</sup> (96%),  $[\alpha]_D^{22} +8.2^\circ$  ( $c$  2.9, CH<sub>3</sub>OH). Hydrolysis of 11 with 5N sodium hydroxide in methanol at 40 °C for 3 h afforded 6-oxo-PGF<sub>1α</sub> (12)<sup>15</sup> (84%),  $[\alpha]_D^{21} -9.6^\circ$  ( $c$  1.04, CH<sub>3</sub>OH).

Thus the present procedure provides very short syntheses of 6-oxo-PGE<sub>1</sub> and -PGF<sub>1α</sub> not via PGI<sub>2</sub> derivatives. In addition, this recipe gives us an alternative way<sup>19</sup> for direct synthesis of 1,4-dicarbonyl compounds starting from α,β-unsaturated enones and nitro-olefins.

#### REFERENCES AND NOTES

1. Prostaglandin Chemistry. XXIII. Part XXII: S. Sugiura, T. Toru, T. Tanaka, N. Okamura, A. Hazato, K. Bannai, K. Manabe, and S. Kurozumi, *Chem. Pharm. Bull.*, **32**, 1248 (1984). Prostaglandin Synthesis. VII. Part VI: M. Suzuki, A. Yanagisawa, and R. Noyori, *Tetrahedron Lett.*, **25**, 1383 (1984).
2. P. Y.-K. Wong, K. U. Malik, F. F. Sun, W. H. Lee, and J. C. McGiff, *Fourth Int. Prostaglandin Conference*, Washington D.C., Abstracts, p. 127 (1979).
3. P. Y.-K. Wong, J. C. McGiff, F. F. Sun, and W. H. Lee, *European J. Pharmacol.*, **60**, 245 (1979).
4. (a) C. P. Quilley, P. Y.-K. Wong, and J. C. McGiff, *European J. Pharmacol.*, **57**, 273 (1979). (b) J. E. Lock, P. M. Olley, F. Coceani, F. Hamilton, and G. Doubilet, *Prostaglandins*, **18**, 303 (1979). (c) F. Coceani, E. Bodach, E. P. White, and P. M. Olley, *ibid.*, **19**, 109 (1980). (d) H. L. Lippton, B. M. Chapnick, A. L. Hyman, and P. J. Kadowitz, *ibid.*, **19**, 299 (1980). (e) R. Mastacchi, S. Fadda, V. Tomasi, and O. Barnabei,

- Prostaglandins and Medicine, 5, 487 (1980). (f) B. Schölkens, G. Beck, W. Bartmenn, U. Lerch, E. Konz, and U. Weithmann, In "Prostaglandins and Thromboxanes", W. Förster, B. Sarembe, and P. Mentz, Eds.; Veb Gustav Fischer Verlag: Jena, 1981; p. 317.
5. "Clinical Pharmacology of Prostacyclin", P. J. Lewis and J. O'Grady, Eds.; Raven Press: New York, 1981.
  6. (a) U. F. Axen and H. W. Smith, Japan Kokai, 53-84942 (1978). (b) M. Hayashi and K. Shimoji, ibid., 54-44639 (1979).
  7. (a) R. A. Johnson, F. H. Lincoln, J. L. Thompson, E. G. Nidy, S. A. Mizesak, and U. Axen, J. Am. Chem. Soc., 99, 4182 (1977). (b) R. A. Johnson, F. H. Lincoln, E. G. Nidy, W. P. Schneider, J. L. Thompson, and U. Axen, ibid., 100, 7690 (1978).
  8. T. Tanaka, T. Toru, N. Okamura, A. Hazato, S. Sugiura, K. Manabe, S. Kurozumi, M. Suzuki, T. Kawagishi, and R. Noyori, Tetrahedron Lett., 24, 4103 (1983).
  9. (a) M. Suzuki, T. Kawagishi, T. Suzuki, and R. Noyori, Tetrahedron Lett., 23, 4057 (1982). (b) M. Suzuki, T. Kawagishi, and R. Noyori, ibid., 23, 5563 (1982). (c) M. Suzuki, A. Yanagisawa, and R. Noyori, ibid., 24, 1187 (1983). (d) Idem, ibid., 25, 1383 (1984).
  10. T. Tanaka, S. Kurozumi, T. Toru, S. Miura, M. Kobayashi, and S. Ishimoto, Tetrahedron, 32, 1713 (1976).
  11. (a) (Nef reaction) W. E. Noland, Chem. Rev., 55, 137 (1955). (b) (reductive Nef reaction) J. E. McMurry and J. Melton, J. Org. Chem., 38, 4367 (1973). (c) (oxidative Nef reaction) N. Kornblum, A. S. Erickson, W. J. Kelly, and B. Henggeler, ibid., 47, 4534 (1982), and references cited therein.
  12. (a) M. Suzuki, T. Suzuki, T. Kawagishi, and R. Noyori, Tetrahedron Lett., 21, 1247 (1980). (b) M. Suzuki, T. Suzuki, T. Kawagishi, Y. Morita, and R. Noyori, Isr. J. Chem., 24, 118 (1984). (c) Use of other organocopper reagents, such as 1-pentynylcopper-hexamethylphosphorous triamide and phenylthiocopper-hexamethylphosphorous triamide instead of copper(I) iodide-tributylphosphine, resulted in the poor formation of the desired three-component coupling product.
  13. A. F. Kluge, K. G. Untch, and J. H. Fried, J. Am. Chem. Soc., 94, 7827 (1972).
  14.  $[\alpha]_D^{22} +67^\circ$  (c 0.117, CH<sub>3</sub>OH): M. Gill and R. W. Rickards, Tetrahedron Lett., 1539 (1979).
  15. The product was identical with the authentic material derived from PGF<sub>2α</sub> via PGI<sub>2</sub> in all respects (IR, NMR, MS, and TLC).
  16. The C-8 epimer might be formed in the trapping the enolate with the nitro-olefin or during the subsequent reaction using the buffered titanium(III) trichloride solution. Equilibration between PGE<sub>1</sub> and its C-8 epimer is also shown by E. G. Daniels, W. C. Krueger, F. P. Kupiecki, J. E. Pike, and W. P. Schneider, J. Am. Chem. Soc., 90, 5894 (1968).
  17. A. Hazato, T. Tanaka, T. Toru, N. Okamura, K. Bannai, S. Sugiura, K. Manabe, and S. Kurozumi, Nippon Kagaku Kaishi, 1983, 1390.
  18. S. Iguchi, H. Nakai, M. Hayashi, H. Yamamoto, and K. Maruoka, Bull. Chem. Soc. Jpn., 54, 3033 (1981).
  19. M. Miyashita, T. Yanami, T. Kumazawa, and A. Yoshikoshi, J. Am. Chem. Soc., 106, 2149 (1984).

(Received in Japan 30 June 1984)